Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)

Fig. 3

Change in patients’ serum inflammatory cytokines levels on days 0 (baseline) and 6 months after the first infusion. Analysis of biomarkers on before (baseline) and 6 months after the first infusion demonstrated a significant reduction in IL-1, and interferon-γ (IFN-γ) in all patients with CLI. Serum levels of tumor necrosis factor alpha (TNF-α) decreased in four cases, but the differences were not statistically significant. *P < 0.05; ns, not significant

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512